Camden Capital, LLC Roivant Sciences Ltd. Transaction History
Camden Capital, LLC
- $896 Million
- Q3 2024
A detailed history of Camden Capital, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Camden Capital, LLC holds 10,000 shares of ROIV stock, worth $125,300. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$125,300% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
311Shares Held
508MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$826 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$824 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$678 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$522 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$443 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.83B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...